XOMA Stock Overview
Operates as a biotech royalty aggregator in the United States and the Asia Pacific. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
XOMA Royalty Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$27.13 |
| 52 Week High | US$35.00 |
| 52 Week Low | US$18.03 |
| Beta | 0.87 |
| 1 Month Change | -10.17% |
| 3 Month Change | 0.78% |
| 1 Year Change | 47.45% |
| 3 Year Change | 23.04% |
| 5 Year Change | -2.13% |
| Change since IPO | -99.43% |
Recent News & Updates
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
Oct 15News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts
Aug 14
Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?
Aug 02XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Jun 29Recent updates
XOMA Royalty's Preferred Shares: High-Yield Dividends From Biotech Royalties
Oct 15News Flash: Analysts Just Made A Notable Upgrade To Their XOMA Royalty Corporation (NASDAQ:XOMA) Forecasts
Aug 14Health Check: How Prudently Does XOMA Royalty (NASDAQ:XOMA) Use Debt?
Aug 02XOMA Corporation: A Hold Rating With Steady Income From Preferred Shares
Jun 29Is XOMA (NASDAQ:XOMA) Using Debt Sensibly?
Apr 03Are Investors Undervaluing XOMA Corporation (NASDAQ:XOMA) By 49%?
Sep 01Bearish: Analysts Just Cut Their XOMA Corporation (NASDAQ:XOMA) Revenue and EPS estimates
Aug 11XOMA GAAP EPS of -$0.53 misses by $0.37, revenue of $0.98M misses by $3.29M
Aug 04Forecast: Analysts Think XOMA Corporation's (NASDAQ:XOMA) Business Prospects Have Improved Drastically
May 08Xoma Gets The Spotlight
Sep 02Things Look Grim For XOMA Corporation (NASDAQ:XOMA) After Today's Downgrade
Aug 20We Think The Compensation For XOMA Corporation's (NASDAQ:XOMA) CEO Looks About Right
May 13Does XOMA (NASDAQ:XOMA) Have A Healthy Balance Sheet?
May 11XOMA EPS misses by $0.55, misses on revenue
May 06XOMA gets milestone payment from Janssen Biotech
May 03XOMA's (NASDAQ:XOMA) Earnings Are Of Questionable Quality
Mar 17Analysts Are More Bearish On XOMA Corporation (NASDAQ:XOMA) Than They Used To Be
Mar 16Is XOMA Corporation (NASDAQ:XOMA) Popular Amongst Institutions?
Mar 09Did You Miss XOMA's (NASDAQ:XOMA) Impressive 140% Share Price Gain?
Feb 02
XOMA: A Royalty Aggregator To Watch
Jan 04XOMA (NASDAQ:XOMA) Has Debt But No Earnings; Should You Worry?
Dec 29XOMA prices $22M offering of series A cumulative perpetual preferred stock
Dec 11Shareholder Returns
| XOMA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.5% | -3.8% | -2.7% |
| 1Y | 47.4% | -2.6% | 23.4% |
Return vs Industry: XOMA exceeded the US Biotechs industry which returned -2.6% over the past year.
Return vs Market: XOMA exceeded the US Market which returned 23.4% over the past year.
Price Volatility
| XOMA volatility | |
|---|---|
| XOMA Average Weekly Movement | 7.0% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: XOMA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: XOMA's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | xoma.com |
XOMA Royalty Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Royalty Corporation Fundamentals Summary
| XOMA fundamental statistics | |
|---|---|
| Market cap | US$319.67m |
| Earnings (TTM) | -US$35.43m |
| Revenue (TTM) | US$21.61m |
14.8x
P/S Ratio-9.0x
P/E RatioIs XOMA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| XOMA income statement (TTM) | |
|---|---|
| Revenue | US$21.61m |
| Cost of Revenue | US$2.04m |
| Gross Profit | US$19.57m |
| Other Expenses | US$55.00m |
| Earnings | -US$35.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.01 |
| Gross Margin | 90.58% |
| Net Profit Margin | -164.00% |
| Debt/Equity Ratio | 139.0% |
How did XOMA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/23 06:22 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
XOMA Royalty Corporation is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Jason Kantor | Credit Suisse |
| Joseph Pantginis | H.C. Wainwright & Co. |